Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
J Infect Dis. 2012 Jun 15;205(12):1821-9. doi: 10.1093/infdis/jis277. Epub 2012 Apr 5.
Quinolone-resistant Neisseria gonorrhoeae (QRNG) arise from mutations in gyrA (intermediate resistance) or gyrA and parC (resistance). Here we tested the consequence of commonly isolated gyrA(91/95) and parC86 mutations on gonococcal fitness.
Mutant gyrA(91/95) and parC86 alleles were introduced into wild-type gonococci or an isogenic mutant that is resistant to macrolides due to an mtrR(-79) mutation. Wild-type and mutant bacteria were compared for growth in vitro and in competitive murine infection.
In vitro growth was reduced with increasing numbers of mutations. Interestingly, the gyrA(91/95) mutation conferred an in vivo fitness benefit to wild-type and mtrR(-79) mutant gonococci. The gyrA(91/95), parC86 mutant, in contrast, showed a slight fitness defect in vivo, and the gyrA(91/95), parC86, mtrR(-79) mutant was markedly less fit relative to the parent strains. A ciprofloxacin-resistant (Cip(R)) mutant was selected during infection with the gyrA(91/95), parC86, mtrR(-79) mutant in which the mtrR(-79) mutation was repaired and the gyrA(91) mutation was altered. This in vivo-selected mutant grew as well as the wild-type strain in vitro.
gyrA(91/95) mutations may contribute to the spread of QRNG. Further acquisition of a parC86 mutation abrogates this fitness advantage; however, compensatory mutations can occur that restore in vivo fitness and maintain Cip(R).
耐喹诺酮淋病奈瑟菌 (QRNG) 是由 gyrA(中度耐药)或 gyrA 和 parC(耐药)突变引起的。在这里,我们测试了常见分离的 gyrA(91/95) 和 parC86 突变对淋球菌适应性的影响。
将突变 gyrA(91/95) 和 parC86 等位基因引入野生型淋球菌或因 mtrR(-79)突变而对大环内酯类药物耐药的同源突变体中。比较野生型和突变型细菌在体外和竞争感染中的生长情况。
随着突变数量的增加,体外生长能力降低。有趣的是,gyrA(91/95)突变赋予野生型和 mtrR(-79)突变淋球菌体内适应性优势。相比之下,gyrA(91/95)、parC86 突变体在体内适应性略差,而 gyrA(91/95)、parC86、mtrR(-79)突变体相对于亲本菌株适应性明显降低。在感染 gyrA(91/95)、parC86、mtrR(-79)突变体时,选择出一种对环丙沙星耐药(Cip(R))的突变体,其中 mtrR(-79)突变被修复,gyrA(91)突变发生改变。这种体内选择的突变体在体外与野生型菌株生长一样良好。
gyrA(91/95)突变可能有助于 QRNG 的传播。进一步获得 parC86 突变会消除这种适应性优势;然而,可能会发生补偿性突变,恢复体内适应性并维持 Cip(R)。